ArticleFrontiers in oncology2026
Multi-omics and spatial transcriptomics decode the ZDHHC9-driven hypoxia-immunosuppressive axis in hepatocellular carcinoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) is a major global health challenge with limited treatment options, highlighting the urgent need for new biomarkers and therapeutic targets. Protein palmitoylation, mediated by ZDHHC enzymes, plays a role in cancer, yet its comprehensive function in HCC development is not fully understood. Methods: We conducted a systematic analysis of the ZDHHC family in HCC. Using data from TCGA and GEO databases, we assessed their expression, prognostic value, association with immune infiltration, and drug sensitivity. Diagnostic biomarkers were identified using ten machine learning algorithms. We then developed a consistent machine learning framework to build a robust multi-gene prognostic signature. The tumor microenvironment was further characterized through integrated single-cell and spatial transcriptomic analyses. The oncogenic role of our primary candidate, ZDHHC9, was functionally tested using siRNA knockdown, Results: Our multi-omics analysis pinpointed ZDHHC9 as both a key prognostic factor and the top diagnostic biomarker. We successfully constructed and validated a powerful multi-gene prognostic signature across independent patient cohorts. High ZDHHC9 expression was associated with an immunosuppressive tumor microenvironment and increased therapy resistance. Single-cell and spatial transcriptomics revealed that ZDHHC9 is specifically upregulated in malignant epithelial cells, especially within hypoxic subpopulations. Pan-cancer analysis further confirmed that ZDHHC9 is frequently dysregulated and prognostically relevant in other cancer types. Functionally, depleting ZDHHC9 significantly inhibited HCC cell proliferation, migration, and invasion Conclusion: This study provides a comprehensive profile of the ZDHHC family in HCC, establishes a robust prognostic model, and nominates ZDHHC9 as a novel diagnostic and prognostic biomarker as well as a promising therapeutic target. The oncogenic function of ZDHHC9 appears to be linked to its role in promoting a hypoxic phenotype and fostering an immunosuppressive microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.